Screener
Kymera Therapeutics KYMR Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Kymera Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
FAQ
- What is Kymera Therapeutics's debt-to-equity?
- Kymera Therapeutics (KYMR) reported debt-to-equity of 0.1× in Q2 2026.
- How has Kymera Therapeutics's debt-to-equity changed year-over-year?
- Kymera Therapeutics's debt-to-equity decreased by 41.1% year-over-year, from 0.1× to 0.1×.
- What is the long-term trend for Kymera Therapeutics's debt-to-equity?
- Over 5 years (2020 to 2025), Kymera Therapeutics's debt-to-equity has grown at a -4.2% compound annual growth rate (CAGR), from 0.1× to 0.1×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Kymera Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude